Stocks to Watch

Malaysia on Monday filed criminal charges against Goldman Sachs and two of the U.S. bank’s former employees in connection with an investigation into suspected corruption and money laundering

Goldman Sachs has been under scrutiny for its role in helping raise $6.5 billion through three bond offerings for 1MDB, which is the subject of investigations in at least six countries.

The U.S. Department of Justice has said about $4.5 billion was misappropriated from 1MDB, including some money that Goldman Sachs helped raise, by high-level officials of the fund and their associates from 2009 through 2014.

3 Pharma Stocks to buy in 2019. The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts.

Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations. Meanwhile, others have sold off as trade-related fears or regulatory hurdles both domestically and abroad increase uncertainty. However, some of these companies have responded by developing new drugs. The following 3 pharma stocks appear particularly well-positioned to benefit from new drugs and demographic tailwinds in 2019.

Investors are turning more positive on the semiconductor industry as they look past demand concerns and start to see value following a bruising October

The Philadelphia Semiconductor Index is off 17 percent from its March record, including a 12 percent rout in October. Analysts say the recent slump has priced in a variety of risks and left stocks undervalued. Furthermore, while some chip categories have seen weakness, the industry overall has been expanding, making it less vulnerable to a slowdown in any single product.